Back to Search
Start Over
Ventricular arrhythmias and sudden death in patients taking ibrutinib
- Source :
- Blood
- Publication Year :
- 2017
- Publisher :
- American Society of Hematology, 2017.
-
Abstract
- To the editor: Ibrutinib, approved by the US Food and Drug Administration (FDA), is an inhibitor of Bruton tyrosine kinase (BTK).[1][1][⇓][2][⇓][3][⇓][4]-[5][5] Ibrutinib use is associated with atrial fibrillation (AF), with an incidence of 5% to 6% after 18 months on therapy[4][4][⇓][5]-[6
- Subjects :
- medicine.medical_specialty
Immunology
030204 cardiovascular system & hematology
Pharmacology
Biochemistry
Sudden death
Food and drug administration
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Internal medicine
medicine
Bruton's tyrosine kinase
In patient
Letter to Blood
biology
business.industry
Atrial fibrillation
Cell Biology
Hematology
medicine.disease
chemistry
030220 oncology & carcinogenesis
Ibrutinib
biology.protein
Cardiology
business
Subjects
Details
- ISSN :
- 15280020 and 00064971
- Volume :
- 129
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi.dedup.....3f1d02fcfe73e9a4b409232dfd150e10